Clinical trials: Urinary Symptoms
Bladder Neoplasm, Neoplasm Recurrence, Local
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
This is a phase 3 randomized, active-controlled, open-label, multicenter study that will be conducted in approximately 120 investigational sites worldwide.
- Conditions
- Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ
- Trial name
- EMBARC-RF (NCT01200992)
- Testing
- EN3348, Mitomycin C
- Where
- 72 sites in United States, Canada and 4 more
- Volunteers
- 84 people
- Sponsor
- Bioniche Life Sciences Inc.
Urinary Bladder, Overactive
Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms
Prospective, double-blind, double-randomised, 2-arm parallel group study. Optimal dose increase. Primary efficacy assessment of OAB symptoms by patient diaries.
- Trial name
- SUNRISE (NCT00801944)
- Testing
- Solifenacin succinate
- Where
- 78 sites in Belgium, Czechia and 12 more
- Volunteers
- 973 people
- Sponsor
- Astellas Pharma Inc
Urinary Bladder, Overactive, Overactive Bladder
Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients
The purpose of the study is to assess patient's persistency in maintaining solifenacin treatment for overactive bladder.
- Trial name
- NCT00985387
- Testing
- Solifenacin
- Where
- 41 sites in South Korea
- Volunteers
- 1,215 people
- Sponsor
- Astellas Pharma Inc
Urge Incontinence
A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.
The purpose of this study is to compare the efficacy and safety of OROS® oxybutynin to that of Ditropan® (immediate-release oxybutynin) for the treatment of patients with urge or mixed urinary incontinence.
- Trial name
- NCT00269750
- Testing
- OROS® oxybutynin or Ditropan®
- Volunteers
- 100 people
- Sponsor
- Alza Corporation, DE, USA
Prostatic Hyperplasia
Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)
The purpose of this study is to determine if transurethral photodynamic therapy with lemuteporfin has a therapeutic effect on lower urinary tract symptoms due to an enlarged prostate.
- Trial name
- NCT00116571
- Testing
- Lemuteporfin for injection, Transurethral drug delivery system, Transurethral light delivery system
- Where
- 9 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- QLT Inc.
Elderly, Pharmacokinetics
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial
This study evaluates the penetration through the blood-brain-barrier of trospium chloride at plasma steady state (Day 10) in elderly subjects with overactive bladder symptoms.
- Conditions
- Elderly, Pharmacokinetics, Overactive Bladder
- Trial name
- NCT00863551
- Testing
- Trospium Chloride
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Allergan
Overactive Bladder, Benign Prostate Hyperplasia
Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)
The purpose of this study is to demonstrate superiority of the solifenacin succinate (treatment) over the placebo (control) based on the change from the baseline in the mean number of urgency episodes per 24 hours after 2 weeks.
- Conditions
- Overactive Bladder, Benign Prostate Hyperplasia, Transurethral Resection of Prostate, Photoselective Vaporization Prostatectomy
- Trial name
- POST-TURP (NCT01747577)
- Testing
- Solifenacin Succinate
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Astellas Pharma Korea, Inc.
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Solid Tumor Malignancies, Colorectal Carcinoma
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383.
- Conditions
- Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC)
- Trial name
- NCT07030257
- Testing
- CP-383
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- Tasca Therapeutics
Stress Urinary Incontinence
Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence
This study evaluates the efficacy and safety of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR; generic name: iltamiocel) compared to a placebo in the reduction of stress incontinence episode frequency in…
- Trial name
- CELLEBRATE (NCT03104517)
- Testing
- AMDC-USR (iltamiocel)
- Where
- 21 sites in United States, United Kingdom
- Volunteers
- 96 people
- Sponsor
- Cook MyoSite
Urinary Incontinence
A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.
A study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men.
- Trial name
- VICTOR (NCT00333112)
- Testing
- solifenacin succinate, tamsulosin
- Where
- 74 sites in United States
- Volunteers
- 398 people
- Sponsor
- Astellas Pharma Inc
Urinary Tract Infection Complicated, Urinary Tract Infection (cUTI)
Clinical Utility of a PCR Compared to Culture and Sensitivity Testing for the Management of cUTI in Adults.
Complicated urinary tract infections (cUTIs) often lead to the overuse of empiric antibiotics, risking inappropriate treatment and contributing to antimicrobial resistance.
- Conditions
- Urinary Tract Infection Complicated, Urinary Tract Infection (cUTI), Urinary Tract Infection (Diagnosis)
- Trial name
- PCR (NCT06996301)
- Testing
- Treatment guided by the PCR results, Treatment guided by the C&S results
- Where
- 6 sites in United States
- Volunteers
- 773 people
- Sponsor
- Doc Lab Inc
Lower Urinary Tract Symptoms, Prostatic Hyperplasia
Efficacy and Safety of Longidaze in the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
The goal of this clinical trial is to learn if Longidaze works to treat lower urinary tract symptoms in adult males with benign prostatic hyperplasia. It will also learn about the safety of Longidaze.
- Trial name
- ADAM (NCT06568718)
- Testing
- bovhyaluronidase azoximer, tamsulosin
- Where
- 3 sites in Russia
- Volunteers
- 229 people
- Sponsor
- NPO Petrovax
Overactive Bladder
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
This is a study to evaluate the efficacy and safety of onabotulinumtoxinA (BOTOX®) compared with placebo, in achieving a 100% reduction in urinary incontinence in patients with overactive bladder (OAB) not properly managed with…
- Trial name
- COMFORT (NCT01945489)
- Testing
- onabotulinumtoxinA, Normal saline
- Where
- 40 sites in United States
- Volunteers
- 254 people
- Sponsor
- Allergan
Urinary Bladder, Overactive, Urinary Bladder, Neurogenic
Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder
This study will describe the prescription conditions of botulinum toxin Type A (Botox®) injection for the treatment of urinary incontinence due to neurogenic detrusor overactivity (NDO) or idiopathic overactive bladder (IOAB) as…
- Trial name
- BOREAL (NCT02673047)
- Testing
- botulinum toxin Type A
- Where
- 50 sites in France
- Volunteers
- 474 people
- Sponsor
- Allergan
Overactive Bladder
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment…
- Trial name
- NCT04103450
- Testing
- Vibegron
- Where
- 35 sites in United States, Poland
- Volunteers
- 276 people
- Sponsor
- Urovant Sciences GmbH
Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination
The purpose of this study is to learn about the safety (the impact of the study drug on the participant's body), effects of the study drug alone or in combination with bevacizumab or sasanlimab, and to find the best dose.
- Conditions
- Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Urothelial Cancer
- Trial name
- LTbR (NCT06448364)
- Testing
- PF-07329640, sasanlimab, bevacizumab
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 4 people
- Sponsor
- Pfizer
Stress Urinary Incontinence
The Nolix Feasibility Efficacy and Safety Study
This study is an open label, prospective, feasibility study with the Nolix device used for temporary treatment of Stress Urinary Incontinence (SUI) in subjects, serving as their own controls.
- Trial name
- NCT04143867
- Testing
- Nolix Device
- Where
- Israel
- Volunteers
- 32 people
- Sponsor
- Gynamics LTD
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms
The hypothesis of the study is to examine whether MCS-2 is safe and effective in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
- Trial name
- MCS_LUTS (NCT01002664)
- Testing
- MCS-2
- Where
- Taiwan
- Volunteers
- 272 people
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
Stress Urinary Incontinence, Urinary Incontinence
Efficacy of a Non-invasive Pelvic Floor Muscle Trainer for Treatment of Stress Urinary Incontinence
The goal of this clinical trial is to assess the efficacy and usability of the electromyography component of the company's pelvic health product in a patient population with stress urinary incontinence.
- Conditions
- Stress Urinary Incontinence, Urinary Incontinence, Pelvic Floor Disorders
- Trial name
- NCT05624645
- Testing
- Pelex Upp
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Pelex